Study: Liposomal CBD Injections Show Weeks-Long Pain Relief and Steady CBD Levels in Goats

OG article by Anthony Martinelli

November 28, 2025

Subcutaneous liposomal CBD injections delivered sustained pain relief and stable plasma levels over weeks in goats with chronic orthopedic pain, per a Frontiers in Pharmacology case study from The Hebrew University of Jerusalem. Two neutered males with congenital spinal/limb deformities, unresponsive to NSAIDs, received 5 mg/kg doses every 6–7 weeks across 14 administrations, showcasing the formulation's slow-release design honed in prior canine trials.

No adverse events occurred; blood panels stayed normal. Pharmacokinetics revealed detectable CBD (peaks 4.4–28.2 ng/mL) and metabolite 7-carboxy-CBD (up to 1,524 ng/mL) for full intervals, with curves flattening toward steady-state post-doses, attributed to liposomal encapsulation boosting bioavailability and tissue accumulation in fat/muscle.

Behaviorally, one goat resumed play and mobility weeks post-injection; the other ceased teeth-grinding—a pain marker—and cooperated better in therapy, with quality-of-life scores peaking in weeks 2–3. Though plasma CBD was low, authors posit therapeutic tissue levels drive analgesia, potentially via anti-inflammatory metabolite effects.

This translational model supports long-acting CBD for large-animal veterinary and human chronic pain, sidestepping oral variability and addiction risks of opioids. Larger controlled trials are needed, but results affirm every-6–7-week dosing as a viable, safe strategy for non-addictive relief.